Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 617-679-5500
Fax: 617-679-5592
Website: http://www.iderapharma.com/
Email: info@iderapharma.com
About Idera Pharmaceuticals, Inc.
Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.For more information, visit www.iderapharma.com.
368 articles about Idera Pharmaceuticals, Inc.
-
Idera Pharmaceuticals, Inc. Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual American Society of Hematology Meeting
12/9/2014
-
Idera Pharmaceuticals, Inc. Announces Appointment Of Robert A. Doody Jr. As Vice President Of Investor Relations And Corporate Communications
12/5/2014
-
Idera Pharmaceuticals, Inc. Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent And Systemic Anti-Tumor Activity In Preclinical Models
12/3/2014
-
Idera Pharmaceuticals, Inc. Names Vincent J. Milano CEO
12/2/2014
-
Idera Pharmaceuticals, Inc. To Present At The Stifel 2014 Healthcare Conference
11/13/2014
-
Idera Pharmaceuticals, Inc. Reports Third Quarter Financial Results And Announces Expansion Of Rare Disease Development Portfolio
11/7/2014
-
Idera Pharmaceuticals, Inc. And Parent Project Muscular Dystrophy Announce Collaboration To Advance New Treatment Approach For Duchenne Muscular Dystrophy
11/7/2014
-
Idera Pharmaceuticals, Inc. Announces Upcoming Presentations Of Data From Oncology Programs At Key Scientific Meetings
11/6/2014
-
Idera Pharmaceuticals, Inc. To Announce Third Quarter 2014 Financial Results And Corporate Update On November 7, 2014
10/30/2014
-
Idera Pharmaceuticals, Inc. Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200
10/14/2014
-
Idera Pharmaceuticals, Inc. Reports Second Quarter 2014 Financial Results And Provides Corporate Update
8/12/2014
-
Idera Pharmaceuticals, Inc. And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis
8/7/2014
-
Idera Pharmaceuticals, Inc. And Collaborators Publish Promising Preclinical Data Targeting Microrna With Gene Silencing Oligonucleotide Technology
8/6/2014
-
Idera Pharmaceuticals, Inc. To Host Conference Call And Webcast To Report Second Quarter 2014 Financial Results
8/5/2014
-
Idera Pharmaceuticals, Inc. To Be Added To The Russell 3000® And Russell 2000#0174; Indexes
6/27/2014
-
Idera Pharmaceuticals, Inc. To Participate In A Panel Discussion At The Piper Jaffray Genomerx Symposium
6/17/2014
-
Idera Pharmaceuticals, Inc. To Present At The Nucleic Acid Summit 2014
6/16/2014
-
Idera Pharmaceuticals, Inc. To Present At The Jefferies and Co. 2014 Global Healthcare Conference
5/28/2014
-
Idera Pharmaceuticals, Inc. Reports First Quarter 2014 Financial Results And Provides Update On Key Programs And Business Strategy
5/13/2014
-
Idera Pharmaceuticals, Inc. Announces Agreement With Abbott Laboratories To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-Cell Lymphoma
5/8/2014